Compare BOF & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOF | NEPH |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 40.1M |
| IPO Year | 2023 | 2004 |
| Metric | BOF | NEPH |
|---|---|---|
| Price | $4.22 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 109.6K | 15.0K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.33 | ★ 1000.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | $3,184,018.00 | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $319.00 |
| Revenue Growth | ★ 258.20 | 32.67 |
| 52 Week Low | $1.93 | $2.66 |
| 52 Week High | $4.95 | $6.42 |
| Indicator | BOF | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 47.62 |
| Support Level | $2.92 | $2.77 |
| Resistance Level | $4.86 | $3.79 |
| Average True Range (ATR) | 0.33 | 0.18 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 84.59 | 27.82 |
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.